An independent data monitoring committee recommended stopping the MONALEESA-2 trial early as results of a pre-planned interim analysis showed the trial met the primary endpoint of progression-free survival (PFS), Novartis AG announced May 18.
MONALEESA-2 is a pivotal Phase III trial of ribociclib (LEE011), a cyclin dependent kinase inhibitor (CDK4/6), in combination with letrozole,...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)